COMPANY RESEARCHCID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
CID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
The September financing announcement supplies a Q1 2027 clinical-start target, rather than evidence that dosing has begun.
2025-12-17: Circle nominates oral cyclin D1 macrocycle CID-165 as development candidate
2026-09-16: Circle raises $92.5 million Series E for oral cyclin D1 macrocycle development
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| CID-078 | Cyclin A/B RxL · Solid tumors | Phase 1 | Clinical programs exist; complete human results were not rechecked in this review |
| CID-165 | Cyclin D1 RxL · Hematologic malignancies / solid tumors | Preclinical | Clinical programs exist; complete human results were not rechecked in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Circle Pharma raised $92.5 million in Series E financing led by The Column Group, with investors including Eli Lilly. Proceeds prioritize CID-165, an oral macrocyclic cyclin D1 RxL inhibitor planned to enter clinical development in the first quarter of 2027, and support the broader pipeline. Reported CID-165 antitumor activity remains preclinical.
Circle Pharma nominated CID-165, an orally available macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program. Preclinical studies supported disruption of the cyclin D1–Rb interaction and activity alone or with other therapies. Candidate nomination is a discovery-to-development milestone, not IND authorization or evidence that human dosing has begun.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.